PRMT5 and chronic myelogenous leukemia, BCR-ABL1 positive: Indeed, the survival, engraftment capability, self-renewal, and low TKI sensitivity intrinsic to CML LSCs has been partially attributable to various methyltransferases, such as DNA methyltransferase 1 (DNMT1) [193], protein arginine methyltransferase 5 (PRMT5) [194], and protein lysine methyltransferase G9A [195], establishing the rationale for clinical implementation of CML-based epigenetic therapeutics.